DEA Boosts Amphetamine Quotas: More Meds for 2025 Without Overproduction
Published Date: 9/19/2025
Notice
Summary
The DEA is changing how much lisdexamfetamine and d-amphetamine can be made in 2025. This affects drug makers who need to follow new production limits to meet demand safely and legally. The update is happening quickly to stick to important deadlines, but it doesn’t involve any new costs for the public.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
2025 Production Limits for Two Stimulants
The DEA adjusted the 2025 aggregate production quota for the Schedule II substances lisdexamfetamine and d-amphetamine (for conversion). Drug manufacturers must follow the new 2025 production limits and the DEA expedited publication to meet the timeframes in 21 U.S.C. 826(h)(1).
No New Public Costs Announced
The DEA stated this adjustment does not involve any new costs for the public. The change is an administrative adjustment to 2025 production quotas and was published quickly to meet statutory timeframes.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-18109, Silicon Metal From Russia; Scheduling of an Expedited Five-Year Review
The government is speeding up a review to decide if special taxes on silicon metal from Russia should stay or go. This affects companies that buy or sell this metal, and could change prices or trade rules soon. The review aims to protect U.S. businesses from unfair competition while keeping things fair and clear.
Next: 2025-18112, Agency Information Collection Activities; Comment Request; AmeriCorps State and National Project Progress Reports
AmeriCorps wants to keep collecting progress reports from groups they fund to make sure projects are on track and making a difference. This affects all AmeriCorps State and National programs, but there’s no new cost or extra paperwork—just a smooth renewal. They’re asking for public feedback before finalizing, so now’s the time to speak up!